Medicare Special Needs Plans — known as SNPs — were designed with a specific promise: that people with the most complex health situations would get coverage tailored to their needs, not a one-size-fits-all insurance product. In 2026, that promise is being tested. A combination of CMS regulatory changes, insurer financial pressures, and shifting Medicaid contract landscapes is producing clear winners and losers among the roughly 9 million Americans enrolled in SNPs. If you or a family member relies on one of these plans, understanding what is changing — and what it means for your specific coverage — is not optional. It is urgent.
There are three types of SNPs, and each is being affected differently in 2026. Chronic Condition Special Needs Plans (C-SNPs) serve people with specific serious illnesses such as diabetes, heart failure, chronic lung disorders, or end-stage renal disease. Institutional Special Needs Plans (I-SNPs) cover people living in nursing facilities or requiring nursing-level care at home. And Dual Eligible Special Needs Plans (D-SNPs) — by far the largest category — serve people who qualify for both Medicare and Medicaid, a population that is disproportionately low-income, older, and medically complex. D-SNPs alone account for the vast majority of SNP enrollment nationally, and they are at the center of the 2026 turbulence.
CMS has been tightening the rules around D-SNPs for several years, and 2026 represents a significant enforcement milestone. Under rules finalized in recent years, D-SNPs are required to achieve deeper integration with state Medicaid programs — meaning the Medicare Advantage insurer must have a formal contract with the state Medicaid agency to coordinate benefits, not just loosely align them. Plans that cannot demonstrate this integration are being required to either upgrade their contracts or exit the D-SNP market. In practical terms, this means some insurers have chosen to exit certain state markets entirely rather than meet the new integration standards, while others have merged their D-SNP products with existing Medicaid managed care contracts to create what CMS calls Highly Integrated Dual Eligible Special Needs Plans, or HIDE SNPs, and Fully Integrated Dual Eligible Special Needs Plans, or FIDE SNPs. For beneficiaries, the difference matters: a FIDE SNP coordinates both your Medicare and Medicaid benefits through a single plan, which can reduce the administrative burden of managing two separate insurance systems and may reduce cost-sharing gaps that fall between the two programs.
The winners in 2026 are largely beneficiaries in states where large insurers — including UnitedHealthcare, Humana, Elevance Health, and Centene — have successfully negotiated integrated D-SNP contracts with state Medicaid agencies. In these markets, dual-eligible beneficiaries may find plans with $0 premiums, expanded supplemental benefits such as dental, vision, hearing, and over-the-counter allowances, and better care coordination. Some integrated D-SNPs in 2026 are offering transportation benefits worth hundreds of dollars annually, meal delivery after hospitalizations, and dedicated care managers who coordinate between primary care physicians and specialists. These benefits are not available in traditional Medicare or standard Medicare Advantage plans, and they can represent thousands of dollars in value for someone managing multiple chronic conditions.
The losers are beneficiaries in markets where insurers have pulled back. When a D-SNP exits a county or state, the beneficiaries enrolled in that plan do not simply lose a few perks — they may lose access to a care team that knows their history, a network of providers who specialize in complex conditions, and coordinated benefits that took months to establish. CMS does provide a Special Enrollment Period when a plan is discontinued, allowing affected beneficiaries to switch to a new plan outside the standard Annual Enrollment Period window of October 15 through December 7. However, the new plan may not have the same network, the same supplemental benefits, or the same level of care coordination. Beneficiaries who are automatically reassigned to a new plan — which CMS can do for low-income subsidy recipients — should review that new plan carefully rather than assuming it meets their needs.
C-SNPs for chronic conditions are also seeing shifts in 2026. Plans serving people with diabetes and cardiovascular disease remain relatively stable in most markets, as these are large patient populations that insurers find financially viable to serve. However, C-SNPs for rarer or more expensive conditions — including autoimmune disorders, certain cancers, and complex neurological conditions — have seen consolidation. If you are enrolled in a C-SNP for a specific condition, verify before December 7 that your plan is continuing in 2026 and that your primary specialists remain in-network. A plan that changes its specialty network mid-year can effectively strand a patient even if the plan itself continues.
For people considering enrolling in a SNP for the first time, the 2026 landscape requires careful research. Not all SNPs are available in all counties — SNP availability is hyperlocal, meaning a plan offered in one ZIP code may not be available three miles away. The Medicare Plan Finder tool at Medicare.gov allows you to enter your ZIP code and filter specifically for Special Needs Plans. When comparing D-SNPs, look beyond the premium — which is often $0 — and examine the plan's star rating, its network of primary care physicians and specialists, its formulary for your specific medications, and the specific supplemental benefits offered. A plan with a 4-star or higher CMS quality rating has demonstrated better performance on care coordination and member satisfaction measures.
State Medicaid agencies play a critical role in D-SNP availability that many beneficiaries do not realize. Because D-SNPs must now have formal contracts with state Medicaid programs, the state government is effectively a gatekeeper for which insurers can offer these plans. States that have been aggressive in negotiating integrated contracts — including California, New York, Texas, Florida, and Ohio — tend to have more D-SNP options available. States with less developed Medicaid managed care infrastructure may have fewer choices. If you are a dual-eligible beneficiary and your current D-SNP is exiting your market, contact your State Health Insurance Assistance Program, known as SHIP, for free one-on-one counseling. SHIP counselors are trained specifically to help beneficiaries navigate plan transitions and can help you compare available options without any sales pressure.
One important protection to understand: if you are enrolled in a SNP and your health status changes so that you no longer qualify — for example, if you leave a nursing facility and therefore no longer meet I-SNP eligibility — you have a Special Enrollment Period to switch to a standard Medicare Advantage plan or return to original Medicare with a stand-alone Part D drug plan. You are not locked into a SNP if your circumstances change. Conversely, if you develop a qualifying chronic condition mid-year, you may be able to enroll in a C-SNP outside of the Annual Enrollment Period using a qualifying life event SEP, though the specific rules depend on the condition and the plan.
The broader policy story behind the 2026 SNP changes is one of CMS attempting to raise the floor on quality for the most vulnerable Medicare beneficiaries while the insurance industry adjusts to tighter margins. Medicare Advantage payment rates, benchmark calculations, and risk adjustment changes have all put pressure on insurer profitability in recent years, and SNPs — which serve expensive, complex patients — are feeling that pressure acutely. The beneficiaries caught in the middle are people who often have the least capacity to navigate a disruptive plan change. If your SNP is continuing unchanged in 2026, consider yourself fortunate — and still review your plan's Annual Notice of Change, which insurers are required to mail by September 30, to confirm that your benefits, network, and drug formulary remain intact.